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Abstract. Spectrophotometric heparin assays which are based on the catalytic effect of
heparin on either the inactivation of thrombin or that of factor Xa by antithrombin III, were
adapted for use in a laboratory batch analyzer. Optimal conditions were determined for assays
using the chromogenic substrates Chromozym-Th and 5-2238 with thrombin, and 3-2222
with factor Xa. Inactivation of the clotting enzyme by antithrombin III was stopped by addi-
tion of chromogenic substrate. Assays thus obtained appeared to be applicable in a wider
range of heparin concentrations and were less dependent on plasma antithrombin III concen-
tration that known manual spectrophotometric methods. The best results were obtained with
the methods based on thrombin inactivation and applying a logarithmic reference curve.
Haemostasis l4: 184-194 (1984)
Introduction
Several spectrophotometric heparin as-
says have been described [1-4]; all are man-
ual methods, some of which are claimed to be
adaptable to automated analyzers. The aim
of this study was to find an automated hepa-
rin assay suited for routine laboratory use
that assesses the heparin level in the thera-
peutic range and above, and that is indepen-
dent of the antithrombin III (AIIID level in
the sample.
Since clinicians frequently aim at plasma
heparin levels between about 200 and 800
U,/1, it was necessary that the reference curves
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used would cover that range. The methods
should, however, also give acceptable esti-
mates of the heparin level in case of oyerdos-
age, and thus the method should render reli-
able values above the higher limit (up to
1,500 u/l).
For ease of automatic data handling it was
important that reference curves would meet a
simple mathematical formula. Most authors
[-3] reported their reference curves to be
linear from 0 to 600 U of heparin/l plasma,
and srggested dilution of samples at higher
levels in order to obtain reliable estimates.
As dilution is time consuming, however, it is
impossible to diflerentiate immediately be-
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tween a small or a large overdose. Moreover,
dilution changes reaction conditions since
the ATIII in the sample is diluted as well. To
find a calibration curve that covers a wider
range of heparin concentrations, we included
in our study the use ofa parabolic and a log-
arithmic fit through reference measure-
ments.
Most amidolytic heparin assays published
negate the influence of the plasma ATIII lev-
els, and the influence of ATIII in the plasma
on the outcome of the heparin determination
has been reported to be moderate [l]. The
linearity of the dose-response curves in the
assay with Xa and 5-2222 was reported to be
dependent on the use ofAtIII in the assay I I , 2].
Heparin is preferably measured under
conditions of a molar excess of other reac-
tants, i.e. ATIII and either thrombin or factor
Xa. An excess of 1,000 times has been sug-
gested as satisfactory [6] to obtain reactions
dependent on heparin concentration only.
Because heparin increases neutralization of
factor Xa by ATIII about 1,300-fold, and that
of thrombin about 2,000-fold [5], a 1,000-
fold excess of free AIIII, however, will bring
the rates of enzyme inactivation by free ATIII
and by the ATIII-heparin complex in the
same order of magnitude.
Therefore, the contribution of free ATIII
to the inactivation of enzyme may not be
neglected a priori. Whether the concentration
of free ATIII in the assay does influence the
outcome of the test depends on the ratio of
the concentration of the heparin-Atlll com-
plex to that of free AIIII, hence on the
amount of ATIII added.
Therefore, we studied the influence of var-
ious ATIII levels in heparinized plasmas on
the outcome of the assays and determined
analytical conditions to minimize this in-
fluence.
Materials
Citrated Plasma. By means of a vacuum system
(Venoject) with a multi-sample needle, 1.8 ml blood
was drawn from the antecubital vein and used for
other purposes. Next, three tubes (Venoject, black
stopper, 4.5 ml, 3.8olo tri-Na-citrate) were drawn and
centrifuged (10 min, 3,500 S', 15 "C) within 15 min.
The plasma thus obtained contained less than 3 X lOe
plateletsil.
Pooled Plasma. Equal volumes of citrated plasma
from 30 healthy donors were mixed and stored ar
- 70 'C in aliquots of I ml.
Heparin was obtained from ko, Emmen, Hol-
land. According to the manufacturer, the solution con-
tained 5,000 USP U/ml of the sodium salt. Dilutions
were made with buflered saline (147 mi1 NaCl,
6.52mMNa2HPO4, 1.62 m,41KH2PO4, pH 7.35).
Antithrombin III from KabiVitrum, Amsterdam
was used. The contents ofeach vial (10 U) were solved
in 10 ml distilled water. One unit is defined as the
activity found in I ml of pooled plasma.
Thrombin used was bovine thrombin from Roche,
Basel. The contents ofeach vial (120 USP units) were
dissolved in 2.40 ml distilled water. Before use I vol
thrombin was diluted with 5 vol buffer.
Factor Xa used was bovine factor Xa from Kabi
Vitrum, Amsterdam. The contents of each vial
(71 nkat) were dissolved in 10 ml distilled water.
Heparin Kil.r. Coatest/Heparin was obtained from
KabiVitrum, Amsterdam. TC-Heparin was obtained
from Boehringer-Mannheim, Amsterdam. These as-
says were performed according to the instructions sup-
plied for kinetic measurement (table I).
Chromogenic substrates used were Tos-Giy-Pro-
Arg-pNA (Chromozym-Th, Boehringer-Mannheim,
Amsterdam), Benz-Ile-Glu-Gly-Arg-pNA . HCI and
H-D-Phe-Pip-Arg-pNA , 2HCl (5-2222 and. 5-2238
both from KabiVitrum, Amsterdam). Each ofthe sub-
strates was dissolved in distilled water.
Bulfer for automated assays (pH 8.4 and I 0.2) con-
tained di-Na-EDTA (7.5 mn{, Tris . HCI (50 mlr')
and NaCl (175 mA4).
Methods
Assays were performed on a 'Corona' batch ana-
lyzer (Clinicon, Amsterdam). This analyzer has a
built-in microprocessor that checks on the linearity of
van Putten/van de Ruit/Beunis/Hemker
change in optical density during the measuring period.
Conditions were set so as to generate an error message
on deviations of more than 2 milliextinctions from
linear, i.e. at deviations larger than 2% ofthe slowest
rate observed in practice. Prediluted plasma samples
were fed into the instrument and there diluted in
duplicate and pipetted into polystyrene cuvettes. The
cuvette was transported into a tunnel ofconstant tem-
perature and (after the preincubation time) Xa or IIa
solution was added. After a programmed incubation
time a chromogenic substrate solution was added and
with a small delay the remaining Xa or IIa activity was
measured. The change in absorbance was calculated,
stored in memory and printed.
We varied the heparin assay conditions to suit the
following demands: (l) Standard deviation ofthe ref-
erence measurements about the calculated reference
line has to be less than 5 9o ofthe range covered. (2) At
the highest heparin level measured, at least halfofthe
original enzyme should be left at the end of the incu-
bation time so as to ensure excess ofthis reactant dur-
Table I. Analytical conditions of the heparin assays
ing the reaction. (3) The same rationale goes for the
antithrombin-Ill concentration. (4) At the end of the
measuring time the reaction rate should be within 20lo
of the starting rate.
The final procedures of the heparin assays are
given in table I. Reference samples were made of
pooled normal plasma spiked with known amounts of
the heparin ofthe same batch as we desired to deter-
mine. Artifrcial variations in the ATIII level were
simulated by variations in the amount added in the
predilution stage, as indicated in table II. The refer-
ence curve was obtained by a logarithmic fit through
reference measurements. Alternatively, a. linear and a
parabolic fit were studied.
Results and Discussion
The spectrophotometric determination of
heparin can most simply be explained as a
reverse titration of clotting enzyme. A fixed
Assay
Chromozym-Th 5-2222
manuall manual2
Chromozym-Th
automated
s-2222 5-2238
automated automated
Predilution, pl
Bu{Ier I
Plasma
ATIII (1.0 U/ml), pl
Diluted plasma, pl
Buffer I, pl
Preincubation time, s
Temperature, 'C
1 0
25
800
100
100
zo0
180
J I
550
50
400
60
r40
456
25
800
100
100
100
100
456
25
550
50
400
75
t25
456
25
Enzyme amount, pl
Xa, nkaVml
IIa, USP units/ml
Incubation time, s
r,000
0.03
180
100
7 . 1
45
r00
8.33
J J
200
7 .1
J J
100
8.33
33
Substrate, pl
Concentration, mmol/l
Measuring time, s
Wavelength, nm
r00
1 . 5
30
405
200
2.0
30
405
100
0.95
22
405
100
1 .0
22
405
100
o.75
22
405
I Boehringer Diagnostica: Produkt informatie TC Heparine, 1980.
2 Kabi Diagnostica: Determination of heparin in plasma with S-22z2,laboratory instruction, April 1977.
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amount of clotting enzyme (E) is added in
excess. The complex (HA) formed (eq. l) by
heparin (H) and ATIII (A), binds and inacti-
vates this enzyme (eq.2), and the remaining
enzyme activity is measured. Because en-
zyme inactivation by ATIII without heparin
(eq. 3) is much slower than by the ArIII-hep-
arin complex, the influence of unbound ATIII
seems neglectable. Available spectrophoto-
metric heparin kits are based on this model
l l ,4 l :
H + A  K r  , H A ,  ( l )
v
HA+E ^ '  ,HAE,  e )
a*s-5l-- 'as, (3)
K r ) K r
where H = n.Ounn, A = antithrombin III,
and E = enzyme (thrombin or Xa).
Table II. Dilution procedure for reference samples
fil1fo6rrgh ATIII is available in molecular
excess (> 20x) over heparin in the Kabi hep-
arin kit, we found enzyme inactivation to be
strongly influenced by both the amount of
AIIII and the amount of heparin at low hep-
arin concentrations, whereas at high heparin
concentrations ATIII appeared to be the main
determinant of the test result (fig. l). As in
the Boehringer kit the plasmas are tested
without predilution, different ATIII levels are
not easily simulated, but for this assay an
even larger influence of AtIU may be ex-
pected because no extra ATIII is added.
The influence of ATIII is not explained by
the titration model above, but it can be ex-
plained by a more complex model of the
action of heparin as has been fottndby Mark-
wardt and Walsmann [7], and confirmed by
others t8-101. In this complex model heparin
u/l Plasma, gl AIIII, pl HEP 200 U/1, trl Bu{Ier, pl
For automated heparin assays with 5-2222
0 100
200 100
400 100
600 100
800 100
To simulate plasma ATIII concentrations of
50o/o: AIUI was 50 pl and buffer was 50 pl more
150 %: ATIII was I 50 pl and buffer was 50 pl less
2000/o: AIIII was 200 gl and buffer was 100 pLl less
100
100
100
100
100
0
100
200
300
400
800
700
600
500
400
For automated heparin assays with 5-2238 or Chromozym-Th
0 50 400
200 50 400
400 50 400
600 50 400
800 50 400
To simulate plasma ATIII concentrations of
500/o: ATIII was 375 pl and bulfer was 25 pl more
150o/o: ATIII was 425 pl and buffer was 25 pl less
2000/o: ATIII was 450 pl and buffer was 50 pl less
0
50
100
1 5 0
200
550
500
450
400
350
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enhances the formation of a complex be-
tween ATIII and a clotting enzyme, but leaves
this complex after it has been formed:
HAE K4  ,H+AE.  (4 )
K z > K a
This extra reaction predicts a multiphase
behavior of enzyme inactivation. In a first
transient phase, concentrations of HA and
HAE are built up. In a second steady phase,
there is constant production of free heparin
(H) and hence constant input in reaction l,
and thus constant inactivation of enzyme as
well. Next, reactions slow down by the in-
creasing influence of decreasing ATIII and
enzyme levels. In the transient and steady
phase, enzyme inactivation is mainly depen-
dent on the heparin concentration and little
on the concentrations of ATIII or enzyme>
whereas in the next phase the reactant
present in the lowest concentration is rate
limiting. Therefore, heparin determinations
should be carried out in the transient and
steady phase, as much as practically possi-
ble.
The transient steady phase model predicts
that the ATIII present in the assay as well as
the incubation time remain important. Any
heparin determination should therefore be
tested on its dependency on ATIII concentra-
tion and on incubation time. So we studied
the influence of various incubation periods
and of extra ATIII added.
We found the inactivation of enzyme to
be in hrst approximation linearly related to
the incubation time, both with and without
heparin (fig.2a-<).In the absence of heparin,
only reaction 3 is responsible for enzyme
inactivation. In the presence of heparin, en-
zyme inactivation is dependent on heparin
concentration. Extrapolation to zero time
(fig.2) indicates the occurrence ofa transient
phase of rapid, heparin-dependent enzyme
Fig. 1 Reference curves ofthe manually performed
heparin kit: Coatest/Heparin (5-2222). From top to
bottom 4 curves with different ATIII concentrations:
500/0, l00o/o, 1500/o and 2000/o f normal plasma.
inactivation. The system therefore behaves
as predicted by the second model.
During the second phase the rate of en-
zyme inactivation is governed by the rate of
heparin release from the ATlll-enzyme-hepa-
rin complex. The enzyme kinetics of this
mechanism resemble those of active site ti-
tration of hydrolytic enzymes I l]. As a prac-
tical consequence, heparin will continue to
bind ATIII to the clotting enzyme during the
incubation time. To ensure that the reaction
rate is suffrciently independent of the ATIII
concentration, the latter reactant will have to
be present in excess (80 times the concentra-
tion ofthe other reactant).
Still at higher heparin concentrations
(above 600 Uil plasma in fig.4), a slight
deviation ofthe linear shape ofthe reference
' ' L . . : 1 , , i  , . " - - i n : ; ' : . ; : i ' j . - r 3 - :  r * : 5 : j - ; j - : i + : ? . ' r .  i r " ' -  : r ' l i  : : 1  ;  i . : r ' - . :  1 . :
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Fig.2. Relative enzyme inhibition at 3 incubation
times for 5 heparin concentrations and 3 chromogenic
substrates. Curves from top to bottom: 200 U/1, 150
U/1, 100 U/1, 50 U/1,0 U/l heparin. a Chromozym-
Th.b3-2222.  c  5 -2238.
line was observed. Because ATIII will be rate
limiting in reactions I and 3, and the enzyme
in reactions 2 and 3, while the velocity of
reaction 4 is limited by the results of reaction
2 on the one hand and influences the velocity
of reaction I on the other. it will be clear that
the shape ofthe reference line can hardly be
expected to be a simple one. The theoretically
correct shape would be governed by at least 6
variables besides heparin (concentrations of
enzyme and AIIII, reaction constants K1
through K6, temperature and incubation
time). Trying to fit 6 (or more) variables to
our data points would be both theoretically
and practically unacceptable. Rather in these
cases one resorts to treating the system as a
black box and tries to find the reference curve
that is most useful in practice (c.f. the logJog
reference curve of the traditional bioassay).
As most desk calculators and even many lab-
oratory analyzers can handle formulas as a
logarithmic and a parabolic frt through the
reference points, we studied whether the lat-
ter two could improve accuracy of readings
from the reference curve at higher heparin
concentrations.
Enzyme inactivation by ATIII without
heparin at the used concentration was about
the same as the inactivation caused by in-
creasing the concentration ofheparin by 150
U/l (frg. 2). So, variations in ATIII in the
assay (A in eq. l-4) may have considerable
influence on the result. Therefore, conditions
in our assays were chosen so that the ATIII in
the sample hardly contributed to the ATIII in
the assay. In the assays based on thrombin
inactivation, only a maximum of l/8 of the
total ATIII present at the reaction originates
from the sample. Increasing ATIII in the as-
say based on factor Xa inactivation, how-
ever, requires a comparably high concentra-
tion of factor Xa and thus large amounts of
lncrbation tirne, 9
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3-2222 as well. Economical constraints on
the use of these reactants forced us to limit
the extra amount of ATIII to a factor 1, in
tests based on factor Xa inactivation. This is
the basis of the fact that assays with thrombin
(and Chromozym-Th or 5-2238) are less in-
fluenced by various ATIII levels than assays
with factor Xa (and 3-2222) are (table III). In
all assays ome influence was found however.
Acceptable results were obtained in a wider
range of heparin concentrations with the
three automated assays ttian with the manual
kit methods.
Residual activity of thrombin and of fac-
tor Xa after the incubation time was approx-
imately constant during at least 1 min after
addition of substrate to the reaction mixture.
This was concluded from the linearity of
recordings ofthe absorbance (not shown) and
from the fact that no error messages (indicat-
ing nonlinearity) were obtained. Since we
measured not longer than until 28 s after the
addition of the substrate, we neyer encoun- ..
tered substrate exhaustion in the assavs.
Table IIL The effect ofAtIII levels on heparin assays
From the results shown in figure 2, we
conclude that there is a linear, time-related
inactivation of enzyme during at least thrice
the incubation time. Since the enzyme activ-
ity continuously decreases during incubation
before adding substrate, but remains con-
stant after this addition, we conclude that
inactivation of enzyme ceased after addition
of substrate solution. The inhibitory effect of
synthetic substrates has been reported before
[3, 8]. It could be the consequence ofgreater
aflinity of the enzyme for the substrate than
for AtIII. The Lineweaver-Burk plots shown
in figure 3 suggest hat V** rather than K*
remains constant at various levels of inhibi;
tor (chromogenic substrate) present at the
inactivation of thrombin by AtI[. This fa-
vors the opinion of competitive inhibition of
ATIII by the chromogenic substrate.
The deviation of the reference measure-
ments about the calculated linear catbration
line was smaller for the automated than for
the manual methods (fig.4). When a parab-
ola is frtted through the reference points this
ATIII Heparin added
to the plasma
u/l
Heparin automatic assay using Heparin
manual assay
using 5-2222
UA
s-2238
u/l
Chromozym-Th 3-2222
U/I UA
50
214
831
57
206
598
t12
286
776
1 1 6
286
769
100
300
800
5070
160
353
780
t44
355
856
100
300
800
r2a
285
790
1 5 1
298
723
100 o/o
l50o/o 140
3il
850
l 3 l
321
809
100
300
800
193
358
202
325
> 800 offcurve >> 800 olf curve
The results of the 9 measurements by each assay were read from the same reference line.
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Fig.3. Lineweaver-Burk plots
revealing the inhibitory eflect of
chromogenic substrates on the inac-
tivation of thrombin by AIIII.
Curves from top to bottom: 3006,
l0o/o, 3o/o, I 0/o and 0 o/o of inhibitor'.
The substrate concentration at the
measuring stage (table I) is consid-
ered l00o/o inhibitor. a Chromo-
zym-Th. b5-2222. c 5-2238.
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Fig.4. Reference curves ofthe heparin assays with
a linear (a), parabolic (b) and logarithmic (c) calibra-
tion curve. The SD of the reference measurements
about the calculated line is shown in table IV. I =
Automated assay with Chromozym-Th and thrombin;
o = automated assay with 5-2238 and thrombin; v =
automated assay with 5-2222 and,factor Xa; a = man-
ual assay with 5-2222 and factor Xa; . = manual assay
with Chromozym-Th and thrombin.
deviation is about the same for all methods.
A linear fit after log transformation gives
intermediate results (table IV).
The parabolic calibration lines of the au-
tomated methods showed no horizontal part
in the range 0-1,000 U/l(frg. 4). The manual
methods, in contrast, revealed zero slope of
the calibration line between 700 and 900 U/1.
For reliable extrapolated estimations of hep-
arin concentration in the range 1,000-1,500
U/1, the logarithmic equation may be applied
for the automated methods (table V). Infor-
. .  
. : . . :
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Table fV. Standard deviations of reference measurements about a linear, a parabolic and a logarithmic
calibration curve
Automated assays Manual assays
Ctuomozym-Th 5-2238 s-2222 s-2222 Chromozym-Th
r93
Linear
Parabolic
Logarithmic
3.5
2.4
3.0
2.0
1 .8
5 . 2
3.6
3 .1
3 .1
10.5
3.3
9.7
14.6
2.2
4.3
The SD are expressed as percentage of the range of heparin covered by the reference measurements'
Table V. Extrapolated estimations of heparin concentration using a parabolic and a logarithmic equation for
the reference curve (the curves were calculated from reference measurements with heparin concentrations rang-
ing 0-800 U/l)
Actual
heparin
concentration
u/l
Logarithmic equation Parabolic equation
Chromozym- 5-2238
Th
s-2222 Chromozym- 3-2238
Th
s-2222
1,000
1,200
1,400
1,600
1,800
2,000
1 , 1 5 3
t ,ztr
t ,4 t9
1,67 5
2,16r
2,369
t,027
r ,2  10
t ,342
9961
l ,635
1,774
I ,081
1,256
1,463
|  5 7 1
1,642
1.687
I , l 4  I
t,243
1,445
oc
oc
oc
oc
oc
oc
oc
oc
oc
oc
oc
oc
oc
oc
oc
oc = Offcurve.
I Bad duplicates.
mation on a moderate overdose, thus ob-
tained, will be of more Yalue to clinicians and
can be presented without the delay ofredeter-
mination after dilution. With the other equa-
tions, no reliable estimate can be obtained in
this range.
Dilution of plasma ATIII had considerable
influence on the results of the original man-
ual methods, as can be read from figure l.
Table VI shows that up to 4O-fold dilution of
samples by saline or buffer, hardly influences
the result of the anti-thrombin-based test in
the modifications here described. Therefore,
even heparin concentrations ofup to 10,000
U/1, as used in open-heart surgery can be
-monitored sulficiently with the automated
methods with thrombin.
Several studies have shown a dilference in
anti-Xa -effect and anti-Ila effect between
heparins of different molecular weight or dif-
ferent origin. We found a catalytic action of
the heparin we used, on both thrombin and
Xa inactivation. It should be emphasized
that for the constr,uction of reference curves
'  
. ,  
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Table vI' Independency on the plasma ATIII concentration: heparin concentration after dilution with buffer(measured with Chromozym_Th and thrombin)
Actual heparin concentration
10,000 u/t 5,000 u/l 2.000 u/l r,000 u/l 500 u/l 250 U/l
Dilution
Result, U/l
l+39
250
l + 1 9
232 245
l+3
249
l + l
249
l+0
259
the same heparin is to be used as that in the
unknown samples. Both automated methods
are subject to further investigation both for
the determination of different heparins, and
for the determination of heparin in actual
patient plasmas.
In conclusion, it can be said that the auto_
mated spectrophotometric methods for hepa_
rin determination we present in this article
are more reliable than the available manual
chromogenic methods and allow heparin to
be determined over a wider range. The meth_
ods based on thrombin inactivation are to be
preferred over those using factor Xa inhibi_
tion because the antithrombin methods are
hardly influenced by the plasma ATIII con_
centration.
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